Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors
暂无分享,去创建一个
Johnathan D. Guest | B. Pierce | G. Efimov | R. Mariuzza | R. Gowthaman | Rui Yin | Y. Serdyuk | Daichao Wu | Alexander Kolesnikov | Anton Shmelev
[1] A. Tonevitsky,et al. T-CoV: a comprehensive portal of HLA-peptide interactions affected by SARS-CoV-2 mutations , 2021, bioRxiv.
[2] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[3] H. Schuitemaker,et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.
[4] P. Dormitzer,et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.
[5] Bjoern Peters,et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 , 2021, Cell Host & Microbe.
[6] B. Haynes,et al. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice , 2021, bioRxiv.
[7] S. Kent,et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity , 2021, Immunity.
[8] C. Szeto,et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses , 2021, Immunity.
[9] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2021, bioRxiv.
[10] P. Dormitzer,et al. Neutralizing Activity of BNT162b2-Elicited Serum , 2021, The New England journal of medicine.
[11] R. Valenta,et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses , 2021, Science Immunology.
[12] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.
[13] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2021, Cell Reports Medicine.
[14] A. Casadevall,et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. , 2021, The Journal of clinical investigation.
[15] Bjoern Peters,et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.
[16] T. Mora,et al. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection , 2021, eLife.
[17] S. Mallal,et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.
[18] J. Mascola,et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.
[19] S. Ladhani,et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.
[20] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[21] H. Rammensee,et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.
[22] I. Wilson,et al. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain , 2020, Cell Reports.
[23] Jared Adolf-Bryfogle,et al. CoV3D: a database of high resolution coronavirus protein structures , 2020, Nucleic Acids Res..
[24] P. Sopp,et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.
[25] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[26] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.
[27] J. McCluskey,et al. Atypical TRAV1-2− T cell receptor recognition of the antigen-presenting molecule MR1 , 2020, The Journal of Biological Chemistry.
[28] S. Mallal,et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.
[29] U. Reimer,et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.
[30] D. Altmann,et al. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection , 2020, Science Immunology.
[31] Martin Linster,et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.
[32] S. Perlman,et al. Lessons for COVID-19 Immunity from Other Coronavirus Infections , 2020, Immunity.
[33] D. Burton,et al. Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.
[34] A. Sette,et al. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns , 2020, Nature Reviews Immunology.
[35] Morten Nielsen,et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.
[36] Qiang Zhou,et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 , 2020, Science.
[37] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[38] B. Pierce,et al. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen , 2020, Nature Communications.
[39] G. A. Efimov,et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors , 2020, Immunity.
[40] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[41] W. Wang,et al. Viral and host factors related to the clinical outcome of COVID-19 , 2020, Nature.
[42] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[43] Meriem Bensouda Koraichi,et al. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection , 2020, bioRxiv.
[44] Morten Nielsen,et al. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data , 2020, Nucleic Acids Res..
[45] M. Chiarini,et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[46] B. Cowie,et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.
[47] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[48] E. Holmes,et al. A new coronavirus associated with human respiratory disease in China , 2020, Nature.
[49] L. Gostin,et al. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. , 2020, JAMA.
[50] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[51] Jia-huai Wang,et al. Structural basis of assembly of the human T cell receptor–CD3 complex , 2019, Nature.
[52] Xin Li,et al. Global Epidemiology of Bat Coronaviruses , 2019, Viruses.
[53] R. Hagedoorn,et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies , 2018, Oncotarget.
[54] G. Alexe,et al. Origin and differentiation of human memory CD8 T cells after vaccination , 2017, Nature.
[55] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[56] A. Bertoletti,et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection , 2016, Vaccine.
[57] K. Lindkvist-Petersson,et al. Structure of Staphylococcal Enterotoxin E in Complex with TCR Defines the Role of TCR Loop Positioning in Superantigen Recognition , 2015, PloS one.
[58] Zhiping Weng,et al. Backbone flexibility of CDR3 and immune recognition of antigens. , 2014, Journal of molecular biology.
[59] Zhiping Weng,et al. Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor , 2014, PLoS Comput. Biol..
[60] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[61] Z. Weng,et al. A flexible docking approach for prediction of T cell receptor–peptide–MHC complexes , 2013, Protein science : a publication of the Protein Society.
[62] R. Mariuzza,et al. Structural basis for self‐recognition by autoimmune T‐cell receptors , 2012, Immunological reviews.
[63] P. Zwart,et al. Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.
[64] Jiahuai Han,et al. Determinants of public T cell responses , 2012, Cell Research.
[65] K. Garcia,et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. , 2011, Immunity.
[66] Hong Yang,et al. Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study , 2011, The Journal of Immunology.
[67] Andrew K. Sewell,et al. Genetic and Structural Basis for Selection of a Ubiquitous T Cell Receptor Deployed in Epstein-Barr Virus Infection , 2010, PLoS pathogens.
[68] L. Fugger,et al. An Alternative Conformation of the T-Cell Receptor α Constant Region , 2010, Journal of molecular biology.
[69] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[70] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[71] J. McCluskey,et al. The shaping of T cell receptor recognition by self-tolerance. , 2009, Immunity.
[72] A. McMichael,et al. T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.
[73] Ralph Baric,et al. A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice , 2007, PLoS pathogens.
[74] Daniel C. Douek,et al. Sharing of T cell receptors in antigen-specific responses is driven by convergent recombination , 2006, Proceedings of the National Academy of Sciences.
[75] Wladek Minor,et al. HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. , 2006, Acta crystallographica. Section D, Biological crystallography.
[76] Robyn L Stanfield,et al. How TCRs bind MHCs, peptides, and coreceptors. , 2006, Annual review of immunology.
[77] Zbyszek Otwinowski,et al. The integration of data reduction and structure solution - from diffraction images to an initial model in minutes , 2005 .
[78] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .
[79] David E. Kim,et al. Computational Alanine Scanning of Protein-Protein Interfaces , 2004, Science's STKE.
[80] Willie R. Watson,et al. A computational and experimental study of slit resonators , 2003 .
[81] J. Drijfhout,et al. Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. , 1995, Human immunology.
[82] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[83] M. Ravid,et al. A Six-Year Follow-up Study , 2016 .
[84] K. Katoh,et al. Improvements in Performance and Usability , 2013 .
[85] G. Davies,et al. Knowns and Unknowns , 2003 .